Hospira Adelaide Pty. Ltd., which is a Pfizer Inc. subsidiary. The plant will now be fully owned by BioCina as per the August 2020 deal. BioCina is a contract development and manufacturing organization (CDMO) focused on the process development and cGMP production of microbial-based treatments and mRNA vaccines.
Manufacturing of cGMP-grade plasmid DNA, which is generated by microbial fermentation, has been added to BioCina’s capabilities. Plasmid DNA is a promising novel therapeutic option as well as a crucial component of current gene therapies such as mRNA vaccines, CAR-T cell therapies, and viral gene replacement therapies. Ian Wisenberg, CEO of BioCina, and Masood Tayebi, founder of BioCina, will expand the company’s…
